{
  "metadata": {
    "case_id": 70,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T18:22:50.568272",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/70_NCT03136861.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/70_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 7,
      "pred_count": 7,
      "similarity_matrix": [
        [
          0.95,
          0.3,
          0.72,
          0.78,
          0.55,
          0.82,
          0.7
        ],
        [
          0.4,
          0.95,
          0.18,
          0.18,
          0.25,
          0.32,
          0.4
        ],
        [
          0.6,
          0.35,
          0.78,
          0.65,
          0.6,
          0.82,
          0.7
        ],
        [
          0.7,
          0.2,
          0.78,
          0.72,
          0.7,
          0.78,
          0.7
        ],
        [
          0.6,
          0.2,
          0.63,
          0.68,
          0.86,
          0.62,
          0.82
        ],
        [
          0.7,
          0.2,
          0.6,
          0.7,
          0.65,
          0.86,
          0.6
        ],
        [
          0.6,
          0.2,
          0.55,
          0.72,
          0.78,
          0.78,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "Secukinumab 150 mg (Group A)",
            "type": "EXPERIMENTAL",
            "description": "Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": {
            "label": "Group A: Secukinumab 150 mg (Treatment Period 1)",
            "type": "EXPERIMENTAL",
            "description": "Patients randomized to secukinumab 150 mg subcutaneous injection at baseline and Weeks 1, 2, 3, and 4 during Treatment Period 1 (baseline to Week 8).",
            "interventionNames": [
              "DRUG: Secukinumab 150 mg"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "Placebo (Group B)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": {
            "label": "Group B: Placebo (Treatment Period 1)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients randomized to placebo subcutaneous injection at baseline and Weeks 1, 2, 3, and 4 during Treatment Period 1 (baseline to Week 8).",
            "interventionNames": [
              "DRUG: Placebo"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "label": "Arm A1",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": {
            "label": "Arm A1: Responders on Secukinumab 150 mg (Treatment Period 2)",
            "type": "EXPERIMENTAL",
            "description": "Patients from Group A who achieved average spinal pain score <4 at Week 8 (responders) were re-assigned to continue secukinumab 150 mg every 4 weeks from Week 8 to Week 24.",
            "interventionNames": [
              "DRUG: Secukinumab 150 mg"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.72,
          "status": "matched",
          "ref_item": {
            "label": "Arm A2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": {
            "label": "Arm A2: Non-responders on Secukinumab 150 mg (Treatment Period 2)",
            "type": "EXPERIMENTAL",
            "description": "Patients from Group A who did not achieve average spinal pain score <4 at Week 8 (non-responders) were re-randomized to continue secukinumab 150 mg every 4 weeks from Week 8 to Week 24.",
            "interventionNames": [
              "DRUG: Secukinumab 150 mg"
            ]
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 4,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "label": "Arm A3",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": {
            "label": "Arm A3: Non-responders escalated to Secukinumab 300 mg (Treatment Period 2)",
            "type": "EXPERIMENTAL",
            "description": "Patients from Group A who did not achieve average spinal pain score <4 at Week 8 (non-responders) were re-randomized to escalate to secukinumab 300 mg every 4 weeks from Week 8 to Week 24.",
            "interventionNames": [
              "DRUG: Secukinumab 300 mg"
            ]
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": 5,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "label": "Arm B1",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": {
            "label": "Arm B1: Placebo switched to Secukinumab 150 mg (Treatment Period 2)",
            "type": "EXPERIMENTAL",
            "description": "Patients from Group B (placebo) were re-randomized to secukinumab 150 mg every 4 weeks from Week 8 to Week 24.",
            "interventionNames": [
              "DRUG: Secukinumab 150 mg"
            ]
          }
        },
        {
          "ref_idx": 6,
          "pred_idx": 6,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "label": "Arm B2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": {
            "label": "Arm B2: Placebo switched to Secukinumab 300 mg (Treatment Period 2)",
            "type": "EXPERIMENTAL",
            "description": "Patients from Group B (placebo) were re-randomized to secukinumab 300 mg every 4 weeks from Week 8 to Week 24.",
            "interventionNames": [
              "DRUG: Secukinumab 300 mg"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.92,
          0.9,
          0.08
        ],
        [
          0.2,
          0.2,
          0.95
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "AIN457",
            "description": "anti IL-17a monoclonal antibody",
            "armGroupLabels": [
              "Arm A1",
              "Arm A2",
              "Arm A3",
              "Arm B1",
              "Arm B2",
              "Placebo (Group B)",
              "Secukinumab 150 mg (Group A)"
            ],
            "otherNames": [
              "secukinumab"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Secukinumab 150 mg",
            "description": "Secukinumab 150 mg administered by subcutaneous injection using 1 mL pre-filled syringes at specified timepoints.",
            "armGroupLabels": [
              "Group A: Secukinumab 150 mg (Treatment Period 1)",
              "Arm A1: Responders on Secukinumab 150 mg (Treatment Period 2)",
              "Arm A2: Non-responders on Secukinumab 150 mg (Treatment Period 2)",
              "Arm B1: Placebo switched to Secukinumab 150 mg (Treatment Period 2)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "AIN457 Placebo",
            "description": "Placebo matching AIN457",
            "armGroupLabels": [
              "Arm A1",
              "Arm A2",
              "Arm B1",
              "Placebo (Group B)"
            ],
            "otherNames": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Placebo administered by subcutaneous injection using 1 mL pre-filled syringes identical in appearance to active treatment at specified timepoints during Treatment Period 1.",
            "armGroupLabels": [
              "Group B: Placebo (Treatment Period 1)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)",
            "description": "The spinal pain numerical rating scale (NRS) is an 11-point scale to assess pain intensity in patients who are able to self-report. It is an 11-point scale from 0-10: 1) \"0\" = no pain. 2) \"10\" = the most intense pain imaginable. To calculate the average spinal pain, the patient was asked to answer 2 questions to get 2 pain ratings, the total spinal pain corresponding to the intensity of spinal pain experienced on an average over 24 hours during the previous week and the nocturnal back pain corresponding to the intensity of spinal pain experienced on an average over the night during the previous week.",
            "timeFrame": "Week 8"
          },
          "pred_item": {
            "measure": "Proportion of patients achieving an average spinal pain score of <4 on a 0-10 numerical rating scale (NRS)",
            "description": "Average spinal pain score is the average of the total score (pain at any time) and the nocturnal score (pain during the night). Patients rated the intensity of spinal pain at any time and the intensity of pain during the night on an 11-point scale (0-10 NRS).",
            "timeFrame": "Week 8"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          1.0
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 1.0,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)",
            "description": "The Bath ankylosing spondylitis disease activity index (BASDAI) consists of a 0 through 10 scale, which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.",
            "timeFrame": "Week 8"
          },
          "pred_item": {
            "measure": "Proportion of patients achieving a BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score of <4",
            "description": "BASDAI is a composite disease activity measure used to assess disease activity in patients with axial spondyloarthritis. A score of <4 indicates low disease activity.",
            "timeFrame": "Week 8"
          }
        }
      ]
    }
  ]
}